- Home
- MGLD vs CTSO Comparison
MGLD vs CTSO Comparison
Compare MGLD & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- CTSO
- Stock Information
- Founded
- MGLD 1996
- CTSO 1997
- Country
- MGLD United States
- CTSO United States
- Employees
- MGLD N/A
- CTSO 149
- Industry
- MGLD Finance/Investors Services
- CTSO Medical/Dental Instruments
- Sector
- MGLD Finance
- CTSO Health Care
- Exchange
- MGLD Nasdaq
- CTSO Nasdaq
- Market Cap
- MGLD 44.8M
- CTSO 49.7M
- IPO Year
- MGLD N/A
- CTSO N/A
- Fundamental
- Price
- MGLD $1.02
- CTSO $0.80
- Analyst Decision
- MGLD
- CTSO Buy
- Analyst Count
- MGLD 0
- CTSO 2
- Target Price
- MGLD N/A
- CTSO $5.38
- AVG Volume (30 Days)
- MGLD 12.3K
- CTSO 140.8K
- Earning Date
- MGLD 11-07-2025
- CTSO 11-13-2025
- Dividend Yield
- MGLD N/A
- CTSO N/A
- EPS Growth
- MGLD N/A
- CTSO N/A
- EPS
- MGLD N/A
- CTSO N/A
- Revenue
- MGLD $29,207,000.00
- CTSO $36,979,520.00
- Revenue This Year
- MGLD N/A
- CTSO $11.93
- Revenue Next Year
- MGLD N/A
- CTSO $21.22
- P/E Ratio
- MGLD N/A
- CTSO N/A
- Revenue Growth
- MGLD N/A
- CTSO 23.89
- 52 Week Low
- MGLD $0.64
- CTSO $0.60
- 52 Week High
- MGLD $2.10
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- MGLD 50.12
- CTSO 56.90
- Support Level
- MGLD $0.90
- CTSO $0.60
- Resistance Level
- MGLD $1.11
- CTSO $0.85
- Average True Range (ATR)
- MGLD 0.07
- CTSO 0.08
- MACD
- MGLD 0.00
- CTSO 0.03
- Stochastic Oscillator
- MGLD 57.14
- CTSO 88.00
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.